Literature DB >> 21744084

Clinical and pathological analysis of 27 patients with combined hepatocellular-cholangiocarcinoma in an Asian center.

Qian Zhan1, Bai-Yong Shen, Xia-Xing Deng, Zhe-Cheng Zhu, Hao Chen, Chen-Hong Peng, Hong-Wei Li.   

Abstract

BACKGROUND: Our purpose was to assess the clinicopathological features and surgical outcomes of combined hepatocellular-cholangiocarcinoma (HCC-CC) in an Asian center.
METHODS: Between 1998 and 2009, 27 patients were diagnosed with combined HCC-CC at our hospital. Their medical records were reviewed and clinicopathological data retrospectively analyzed.
RESULTS: The 27 patients included 24 (88.9%) males and 3 (11.1%) females with a mean age of 58.26 ± 11.18 years. Cirrhosis was present in 10 patients (37.0%), and 12 patients had hepatitis C or hepatitis B virus infection. Serum alpha fetoprotein was >20 ng/ml in 7 of the 19 patients in whom it was measured (36.8%). Twenty-five patients underwent hepatic resections and 2 received liver transplantations. Five (18.5%) patients had separate HCC and CC within the same liver (type I), 21 (77.8%) had tumors with mixed components (type II), and 1 patient had a type III tumor (3.7%). Of 22 patients with immunohistochemical data, 19 (86.4%) were cytokeratin (CK) 7-positive, 20 (90.9%) were CK19-positive, and 4 (18.2%) were CK20-positive. Mean follow-up was 25.8 months. The 1- and 2-year survival rates were 72.5 and 49.4%, respectively. The 1- and 2-year disease-free survival rates were 54.2 and 41.3%, respectively. Symptoms at the time of diagnosis, and regional lymph node metastases, were associated with higher mortality and recurrence.
CONCLUSIONS: Lymph node metastasis and positive resection margins are important factors affecting HCC-CC surgical outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21744084     DOI: 10.1007/s00534-011-0417-2

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  10 in total

1.  Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.

Authors:  Yan-Ming Zhou; Xiao-Feng Zhang; Lu-Peng Wu; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

2.  Concurrent occurrence of primary hepatocellular and cholangiocellular carcinoma in the different part of the liver: a case report.

Authors:  Xinying Li; Wei Jiang; Tiecheng Feng; Zhiming Wang
Journal:  Int J Clin Exp Med       Date:  2012-08-22

Review 3.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

4.  Management of combined hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2018-10-17

5.  A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Shaffer R S Mok; Sachin Mohan; Navjot Grewal; Adam B Elfant; Thomas A Judge
Journal:  J Gastrointest Oncol       Date:  2016-08

6.  Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database.

Authors:  Valery Vilchez; Malay B Shah; Michael F Daily; Luis Pena; Ching-Wei D Tzeng; Daniel Davenport; Peter J Hosein; Roberto Gedaly; Erin Maynard
Journal:  HPB (Oxford)       Date:  2016-01-07       Impact factor: 3.647

7.  Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.

Authors:  Qian Zhao; Wen-Long Yu; Xin-Yuan Lu; Hui Dong; Yi-Jin Gu; Xia Sheng; Wen-Ming Cong; Meng-Chao Wu
Journal:  Chin J Cancer       Date:  2016-08-24

8.  Comparison of Imaging and Clinically Relevant Features of Combined Hepatocellular Carcinoma and Cholangiocarcinoma with Hepatocellular Carcinoma.

Authors:  Xialing Huang; Yajuan Li; Liling Long
Journal:  Med Sci Monit       Date:  2019-11-14

9.  Comprehensive radiomics nomogram for predicting survival of patients with combined hepatocellular carcinoma and cholangiocarcinoma.

Authors:  You-Yin Tang; Yu-Nuo Zhao; Tao Zhang; Zhe-Yu Chen; Xue-Lei Ma
Journal:  World J Gastroenterol       Date:  2021-11-07       Impact factor: 5.742

10.  Anatomical liver resection improves surgical outcomes for combined hepatocellular-cholangiocarcinoma: A propensity score matched study.

Authors:  Wen-Qiang Wang; Jian Li; Bin-Yong Liang; Xing Lv; Rong-Hua Zhu; Jin-Lin Wang; Zhi-Yong Huang; Shu-Hong Yang; Er-Lei Zhang
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.